As an ally for the LGBTQ+ community, I am both honoured and delighted to have been asked to contribute the foreword for this year’s OPEN Global Pride Journal. In considering the words to share with you, it has given me time to reflect on this year’s theme of "Together in Pride" and what this means for our colleagues, culture and values, and the role I can play.
NEW YORK, May 31, 2024 – Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for fidanacogene elaparvovec, a gene therapy for the treatment of severe and moderately severe hemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors and without detectable antibodies to variant AAV serotype Rh74.
FOR IMMEDIATE RELEASE – May 21, 2024 - NEW YORK, NY.,
Hospira, Inc., a Pfizer company (“Pfizer”), is voluntarily recalling the lots listed in the table below of Buprenorphine Hydrochloride Injection CarpujectTM Units and Labetalol Hydrochloride Injection, USP CarpujectTM Units to the User level. The recall was initiated due to the potential for incomplete crimp seals; one customer complaint has been received for one leaking unit.